|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
3
|
Dai H, Li R, Wheeler T, et al: Enhanced
survival in perineural invasion of pancreatic cancer: an in vitro
approach. Hum Pathol. 38:299–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kleeff J, Beckhove P, Esposito I, et al:
Pancreatic cancer microenvironment. Int J Cancer. 121:699–705.
2007. View Article : Google Scholar
|
|
5
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reymond N, Riou P and Ridley AJ: Rho
GTPases and cancer cell transendothelial migration. Methods Mol
Biol. 827:123–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garcia-Mata R, Boulter E and Burridge K:
The ‘invisible hand’: regulation of RHO GTPases by RHOGDIs. Nat Rev
Mol Cell Biol. 12:493–504. 2011.
|
|
8
|
Scherle P, Behrens T and Staudt LM:
Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding
protein, is expressed preferentially in lymphocytes. Proc Natl Acad
Sci USA. 90:7568–7572. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho HJ, Baek KE and Yoo J: RhoGDI2 as a
therapeutic target in cancer. Expert Opin Ther Targets. 14:67–75.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho HJ, Baek KE, Park SM, et al: RhoGDI2
expression is associated with tumor growth and malignant
progression of gastric cancer. Clin Cancer Res. 15:2612–2619. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Wang J, Zhang X, Zeng Y, Liang L and
Ding Y: Overexpression of RhoGDI2 correlates with tumor progression
and poor prognosis in colorectal carcinoma. Ann Surg Oncol.
19:145–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y and Zhang B: D4-GDI, a Rho GTPase
regulator, promotes breast cancer cell invasiveness. Cancer Res.
66:5592–5598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gildea JJ, Seraj MJ, Oxford G, et al:
RhoGDI2 is an invasion and metastasis suppressor gene in human
cancer. Cancer Res. 62:6418–6423. 2002.PubMed/NCBI
|
|
14
|
Ma L, Xu G, Sotnikova A, et al: Loss of
expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in
Hodgkin lymphoma. Br J Haematol. 139:217–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dransart E, Olofsson B and Cherfils J:
RhoGDIs revisited: novel roles in Rho regulation. Traffic.
6:957–966. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boulter E, Garcia-Mata R, Guilluy C, et
al: Regulation of Rho GTPase crosstalk, degradation and activity by
RhoGDI1. Nat Cell Biol. 12:477–483. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morin A, Cordelières FP, Cherfils J and
Olofsson B: RhoGDI3 and RhoG: vesicular trafficking and
interactions with the Sec3 exocyst subunit. Small GTPases.
1:142–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lelias JM, Adra CN, Wulf GM, et al: cDNA
cloning of a human mRNA preferentially expressed in hematopoietic
cells and with homology to a GDP-dissociation inhibitor for the rho
GTP-binding proteins. Proc Natl Acad Sci USA. 90:1479–1483. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boulter E and Garcia-Mata R: RhoGDI: A
rheostat for the Rho switch. Small GTPases. 1:65–68. 2010.
View Article : Google Scholar
|
|
20
|
Harding MA and Theodorescu D: RhoGDI
signaling provides targets for cancer therapy. Eur J Cancer.
46:1252–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niu H, Li H, Xu C and He P: Expression
profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung
cancer metastasis. Oncol Rep. 24:465–471. 2010.PubMed/NCBI
|
|
22
|
Cho HJ, Baek KE, Kim IK, et al:
Proteomics-based strategy to delineate the molecular mechanisms of
RhoGDI2-induced metastasis and drug resistance in gastric cancer. J
Proteome Res. 11:2355–2364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Theodorescu D, Sapinoso LM, Conaway MR,
Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of
metastasis suppressor RhoGDI2 is associated with decreased survival
for patients with bladder cancer. Clin Cancer Res. 10:3800–3806.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dovas A and Couchman JR: RhoGDI: multiple
functions in the regulation of Rho family GTPase activities.
Biochem J. 390:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
DerMardirossian C and Bokoch GM: GDIs:
central regulatory molecules in Rho GTPase activation. Trends Cell
Biol. 15:356–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hart MJ, Maru Y, Leonard D, Witte ON,
Evans T and Cerione RA: A GDP dissociation inhibitor that serves as
a GTPase inhibitor for the Ras-like protein CDC42Hs. Science.
258:812–815. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chuang TH, Xu X, Knaus UG, Hart MJ and
Bokoch GM: GDP dissociation inhibitor prevents intrinsic and GTPase
activating protein-stimulated GTP hydrolysis by the Rac GTP-binding
protein. J Biol Chem. 268:775–778. 1993.PubMed/NCBI
|
|
28
|
Schunke D, Span P, Ronneburg H, et al:
Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor
beta in breast cancer cells. Cancer Res. 67:10694–10702. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cho HJ, Baek KE, Nam IK, et al: PLCγ is
required for RhoGDI2-mediated cisplatin resistance in gastric
cancer. Biochem Biophys Res Commun. 414:575–580. 2011.
|
|
30
|
Friedl P and Wolf K: Tumour-cell invasion
and migration: diversity and escape mechanisms. Nat Rev Cancer.
3:362–374. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Binker MG, Binker-Cosen AA, Richards D,
Oliver B and Cosen-Binker LI: EGF promotes invasion by PANC-1 cells
through Rac1/ROS-dependent secretion and activation of MMP-2.
Biochem Biophys Res Commun. 379:445–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
